These antibodies can act by inhibiting various mucosal HIV-1 entry pathways such as epithelial transcytosis (181, 182) and by binding to the HIV-1 virus or by neutralizing the virus to prevent infection of CD4+ T cells by primary HIV-1 isolates (183). This evidence concerns the gene CD4 and infection.